Ethical challenges associated with pragmatic and cluster RCTs

14 September 2024 - Pragmatic and cluster RCTs offer opportunities for advancing research but present ethical challenges. ...

Read more →

Weighing the benefits and risks of proliferating observational treatment assessments: observational cacophony, randomised harmony

31 July 2020 - Amid the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, substantial effort is being directed toward ...

Read more →

Overlap weighting: a propensity score method that mimics attributes of a randomised clinical trial

5 May 2020 - Evidence obtained from clinical practice settings that compares alternative treatments is an important source of information about ...

Read more →

Randomised clinical trials and COVID-19: managing expectations

4 May 2020 - Despite the millions of cases and hundreds of thousands of deaths that have occurred in this devastating ...

Read more →

A strategy for improving U.S. health care delivery — conducting more randomised, controlled trials

16 April 2020 - Despite the prominence of randomised, controlled trials in medical research, they have rarely been used to evaluate ...

Read more →

Randomised clinical trials of artificial intelligence

17 February 2020 - As patient data are increasingly captured digitally, the opportunities to deploy artificial intelligence, especially machine learning, ...

Read more →

The magic of randomisation versus the myth of real world evidence

12 February 2020 - Non-randomised observational analyses have been promoted as alternatives to randomised clinical trials.  ...

Read more →

Where next for randomised controlled trials in global health?

26 October 2019 - The 2019 Nobel Memorial Prize in Economic Sciences was awarded to three economists—Esther Duflo, Abhijit Bannerjee, and ...

Read more →

The stepped wedge cluster randomised trial: what it is and when it should be used

1 April 2019 - The basic premise of a stepped wedge cluster randomised trial is that all clusters start in the ...

Read more →

Treatment effects in multi-centre randomised clinical trials

1 March 2019 - It is common for treatments to be evaluated in clinical trials that involve many sites or centres, ...

Read more →

Post-marketing modifications of drug labels for cancer drugs approved by the US FDA between 2006 and 2016 with and without supporting randomized controlled trials

11 April 2018 - Modifications in cancer drug indications, dosing, and related toxicities after FDA approval are common. It is unclear ...

Read more →

Finding RCTs of new drugs: searches in trial registries require specific adaptations

5 January 2018 - In their article in the Journal of Clinical Epidemiology, Marco Knelangen, Elke Hausner, Sibylle Sturtz, and ...

Read more →

Many FDA approved cancer drugs might lack clinical benefit

21 December 2017 - New research shows that less than half of the randomised controlled trials that support the approval of ...

Read more →

Mendelian randomisation

21 November 2017 - Mendelian randomisation uses genetic variants to determine whether an observational association between a risk factor and an ...

Read more →

Negative control outcomes: a tool to detect bias in randomised trials

27 December 2016 - Investigators have several design, measurement, and analytic tools to detect and reduce bias in epidemiological studies. One ...

Read more →